Authors' reply Free

Preview this article:

There is no abstract available.

Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.29045-0
2006-07-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/micro/152/7/1895.html?itemId=/content/journal/micro/10.1099/mic.0.29045-0&mimeType=html&fmt=ahah

References

  1. Duverger A, Jackson R. J, van Ginkel F. W. 7 other authors 2006; Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J Immunol 176:1776–1783 [CrossRef]
    [Google Scholar]
  2. Hatheway C. L. 1976; Toxoid of Clostridium botulinum type F: purification and immunogenicity studies. Appl Environ Microbiol 31:234–242
    [Google Scholar]
  3. Hatheway C. L, McCroskey L. M, Lombard G. L, Dowell V. R. Jr 1981; Atypical toxin variant of Clostridium botulinum type B associated with infant botulism. J Clin Microbiol 14:607–611
    [Google Scholar]
  4. Lee J. C, Yokota K, Arimitsu H. 7 other authors 2005; Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 151:3739–3747 [CrossRef]
    [Google Scholar]
  5. Oguma K, Syuto B, Iida H, Kubo S. 1980; Antigenic similarity of toxins produced by Clostridium botulinum type C and D strains. Infect Immun 30:656–660
    [Google Scholar]
  6. Oguma K, Agui T, Syuto B, Kimura K, Iida H, Kubo S. 1982; Four different monoclonal antibodies against type C1 toxin of Clostridium botulinum . Infect Immun 38:14–20
    [Google Scholar]
  7. Oguma K, Murayama S, Syuto B, Iida H, Kubo S. 1984; Analysis of antigenicity of Clostridium botulinum type C1 and D toxins by polyclonal and monoclonal antibodies. Infect Immun 43:584–588
    [Google Scholar]
  8. Sugiyama H, Ohishi I, Dasgupta B. R. 1974; Evaluation of type A botulinal toxin assays that use antitoxin to crystalline toxin. Appl Microbiol 27:333–336
    [Google Scholar]
  9. Sun H. X. 2006; Adjuvant effect of Achyranthes bidentata saponins on specific antibody and cellular response to ovalbumin in mice. Vaccine 24:3432–3439 [CrossRef]
    [Google Scholar]
  10. Suzuki T, Watanabe T, Mutoh S, Hasegawa K, Kouguchi H, Sagane Y, Fujinaga Y, Oguma K, Ohyama T. 2005; Characterization of the interaction between subunits of the botulinum toxin complex produced by serotype D through tryptic susceptibility of the isolated components and complex forms. Microbiology 151:1475–1483 [CrossRef]
    [Google Scholar]
  11. Torii Y, Tokumaru Y, Kawaguchi S, Izumi N, Maruyama S, Mukamoto M, Kozaki S, Takahashi M. 2002; Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. Vaccine 20:2556–2561 [CrossRef]
    [Google Scholar]
  12. Vertiev Y. V, Zdanovsky A. G, Shevelev A. B, Borinskaya S. A, Gening E. L, Martin T, Ivanov P. A, Yankovsky N. K. 2001; Recombinant Listeria strains producing the nontoxic L-chain of botulinum neurotoxin A in a soluble form. Res Microbiol 152:563–567 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.29045-0
Loading
/content/journal/micro/10.1099/mic.0.29045-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed